RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM) Conference

Gilbert, Mark R, Wang, Meihua, Aldape, Kern et al. (2010). RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM) . NEURO-ONCOLOGY, 12 39-39.

International Collaboration

cited authors

  • Gilbert, Mark R; Wang, Meihua; Aldape, Kern; Sorensen, A Gregory; Mikkelsen, Tom; Bokstein, Felix; Woo, Shaio Y; Chmura, Steven J; Choucair, Ali K; Mehta, Minesh

sustainable development goals

authors

date/time interval

  • December 9, 2010 -

publication date

  • November 1, 2010

webpage

published in

keywords

  • Clinical Neurology
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • Science & Technology

Location

  • Hollywood, FL

Conference

  • Advances in Inflammatory Bowel Diseases Crohns and Colitis Foundations National Clinical and Research Conference

publisher

  • OXFORD UNIV PRESS INC

start page

  • 39

end page

  • 39

volume

  • 12